Bird & Bird advises Paladin Capital Group on Constructive Bio’s $58m Series A Financing
Contacts
Partner
UK
I'm co-head of our London corporate team where I have over 20 years' experience advising clients on corporate transactions, including mergers and acquisitions (and disposals), equity capital markets transactions, private equity and venture capital investments/exits, joint ventures and corporate reorganisations.
International law firm Bird & Bird has advised Paladin Capital Group on its participation in Constructive Bio’s $58m Series A Financing, alongside other lead investors Ahren and OMX Ventures.
Constructive Bio, the pioneering synthetic genomics company, will use the funding to further develop its groundbreaking technology that writes genomes from scratch and creates entirely new biomolecules.
Paladin Capital Group was founded in 2001 and has offices in Washington DC, New York, London, Luxembourg, and Silicon Valley. As a multi-stage investor, Paladin’s core strength is identifying, supporting and investing in innovative companies that develop promising, early-stage technologies to address the critical cyber and advanced technological needs of both commercial and government customers.
The Bird & Bird Team was led by James Baillieu (partner, Corporate) and included Will Alms and Tamara Akl (associates, Corporate) as well as Saskia King (partner, FDI) and Tenisha Cramer (associate, FDI).
Paul Conley, Managing Director at Paladin Capital Group and CEO of General Inception, a deep tech venture studio which has supported Constructive Bio since its foundation and serves on Constructive Bio’s board, said: “It has been amazing to witness the evolution of Constructive Bio’s truly unique bioengineering and biomanufacturing platform technologies. We are honoured to be backing this impressive team as they move swiftly to realise the full potential of the technology with breakthrough medicines, enzymes and biomaterials in the future. It was a pleasure working with Bird & Bird, whose venture capital and life sciences expertise helped us to successfully complete the deal.”
James Baillieu, Corporate Partner at Bird & Bird commented: “We were delighted to advise long-standing client Paladin Capital on this transaction. Constructive Bio is a truly exciting company and we wish the whole team there the very best as they build novel materials and products that promises to revolutionise the drug manufacturing and discovery process. It is another great example of the excellent work carried out by our market leading venture capital and life sciences practices.”